AIMS: To use pharmacostatistical models to characterize tolcapone's pharmacokinetics in parkinsonian patients, and to identify any demographic subpopulations which may be at risk of either under- or over-exposure to this catechol-O-methyltransferase (COMT) inhibitor. METHODS:Four hundred and twelve patients participated in three multicentre, parallel, double-blind, placebo-controlled, dose-finding studies and received either placebo or tolcapone (50, 200 or 400 mg three times daily) in addition to levodopa/decarboxylase inhibitor therapy. Sparse blood samples were obtained from 275 patients for tolcapone assay and the concentrations (1414 in total) were analysed using the NONMEM program. RESULTS: The pharmacokinetic model which best described the data was a two-compartment open model with first-order absorption and possibly a lag-time. Tolcapone pharmacokinetics were shown to be stable, with no systematic trend between 2 and 6 weeks of treatment. The absorption of the drug was shown to be rapid and concomitant food intake had only a minor effect on the relative bioavailability (10-20% reduction compared with fasting). The overall clearance of tolcapone could be estimated with good precision (approximately 4. 5-5 l h-1 ), and none of the investigated covariates (e.g. sex, age, body weight) had any clinically significant influence on this parameter. The volume of distribution showed relatively high variability and was calculated to be approximately 30 l, leading to an estimated half-life in patients of approximately 5-8 h. CONCLUSIONS: Using sparse concentrations and mixed effect-effects modelling analysis it is possible to describe the pharmacokinetics of tolcapone in parkinsonian populations. The parameter estimates obtained agreed with those obtained from conventional pharmacokinetic studies and no subpopulation was shown to be at risk of either under- or over-exposure to tolcapone.
RCT Entities:
AIMS: To use pharmacostatistical models to characterize tolcapone's pharmacokinetics in parkinsonianpatients, and to identify any demographic subpopulations which may be at risk of either under- or over-exposure to this catechol-O-methyltransferase (COMT) inhibitor. METHODS: Four hundred and twelve patients participated in three multicentre, parallel, double-blind, placebo-controlled, dose-finding studies and received either placebo or tolcapone (50, 200 or 400 mg three times daily) in addition to levodopa/decarboxylase inhibitor therapy. Sparse blood samples were obtained from 275 patients for tolcapone assay and the concentrations (1414 in total) were analysed using the NONMEM program. RESULTS: The pharmacokinetic model which best described the data was a two-compartment open model with first-order absorption and possibly a lag-time. Tolcapone pharmacokinetics were shown to be stable, with no systematic trend between 2 and 6 weeks of treatment. The absorption of the drug was shown to be rapid and concomitant food intake had only a minor effect on the relative bioavailability (10-20% reduction compared with fasting). The overall clearance of tolcapone could be estimated with good precision (approximately 4. 5-5 l h-1 ), and none of the investigated covariates (e.g. sex, age, body weight) had any clinically significant influence on this parameter. The volume of distribution showed relatively high variability and was calculated to be approximately 30 l, leading to an estimated half-life in patients of approximately 5-8 h. CONCLUSIONS: Using sparse concentrations and mixed effect-effects modelling analysis it is possible to describe the pharmacokinetics of tolcapone in parkinsonian populations. The parameter estimates obtained agreed with those obtained from conventional pharmacokinetic studies and no subpopulation was shown to be at risk of either under- or over-exposure to tolcapone.
Authors: H Baas; A G Beiske; J Ghika; M Jackson; W H Oertel; W Poewe; G Ransmayr Journal: J Neurol Neurosurg Psychiatry Date: 1997-10 Impact factor: 10.154
Authors: J Dingemanse; K Jorga; G Zürcher; M Schmitt; G Sedek; M Da Prada; P Van Brummelen Journal: Br J Clin Pharmacol Date: 1995-09 Impact factor: 4.335
Authors: J Dingemanse; K M Jorga; M Schmitt; R Gieschke; B Fotteler; G Zürcher; M Da Prada; P van Brummelen Journal: Clin Pharmacol Ther Date: 1995-05 Impact factor: 6.875
Authors: J Dingemanse; K Jorga; G Zürcher; B Fotteler; G Sedek; T Nielsen; P van Brummelen Journal: Eur J Clin Pharmacol Date: 1996 Impact factor: 2.953
Authors: Peter L Bonate; Malidi Ahamadi; Nageshwar Budha; Amparo de la Peña; Justin C Earp; Ying Hong; Mats O Karlsson; Patanjali Ravva; Ana Ruiz-Garcia; Herbert Struemper; Janet R Wade Journal: J Pharmacokinet Pharmacodyn Date: 2016-02-02 Impact factor: 2.745